Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
August 17, 2022 06:21 AM EDTUpdated August 19, 04:07 AM
R&D

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Amber Tong

John Carroll

Editor & Founder

Sanofi is of­fi­cial­ly giv­ing up on its oral SERD.

The French drug­mak­er put out word Wednes­day morn­ing that it will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times